Joachim Strassburg

Joachim Strassburg

Auto-generated profile, based on publicly available information

Joachim Strassburg

Department of General and Visceral Surgery, Vivantes Klinikum im Friedrichshain, Berlin, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RRReinhard Ruppert
Reinhard Ruppert
TJTheodor Junginger
Theodor Junginger
RKRainer Kube
Rainer Kube
JSJoachim Strassburg
Joachim Strassburg
ALAndreas Lewin
Andreas Lewin
Susanne MerkelSusanne Merkel
Susanne Merkel
PURPOSE: We investigated whether neoadjuvant chemoradiotherapy (nCRT) in patients with rectal cancer can be restricted to those at high risk of locoregional recurrence (LR) without compromising oncological outcomes. PATIENTS AND METHODS: In a prospective multicenter interventional study, patients with rectal cancer (cT2-4, any cN, cM0) were classified according to the minimal distance between the tumor, suspicious lymph nodes or tumor deposits, and mesorectal fascia (mrMRF). Patients with a distance >1 mm underwent up-front total mesorectal excision (TME; low-risk group), whereas those with a distance ≤1 mm and/or cT4 and cT3 tumors in the lower rectal third received nCRT followed by TME surgery (high-risk group). The primary end point was 5-year LR rate. RESULTS: Of the 1,099 patients included, 884 (80.4%) were treated according to the protocol. A total of 530 patients (60%) underwent up-front surgery, and 354 (40%) had nCRT followed by surgery. Kaplan-Meier analyses revealed 5-year LR rates of 4.1% (95% CI, 2.7 to 5.5) for patients treated per protocol, 2.9% (95% CI, 1.3 to 4.5) after up-front surgery, and 5.7% (95% CI, 3.2 to 8.2) after nCRT followed by surgery. The 5-year rate of distant metastases was 15.9% (95% CI, 12.6 to 19.2) and 30.5% (95% CI, 25.4 to 35.6), respectively. In a subgroup analysis of 570 patients with lower and middle rectal third cII and cIII tumors, 257 (45.1%) were at low-risk. The 5-year LR rate in this group was 3.8% (95% CI, 1.4 to 6.2) after up-front surgery. In 271 high-risk patients (involved mrMRF and/or cT4), the 5-year rate of LR was 5.9% (95% CI, 3.0 to 8.8) and of metastases 34.5% (95% CI, 28.6 to 40.4); disease-free survival and overall survival were the worst. CONCLUSION: The findings support the avoidance of nCRT in low-risk patients and suggest that in high-risk patients, neoadjuvant therapy should be intensified to improve prognosis.

14 August 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
FGFor the OCUM group
For the OCUM group
MKMartin E. Kreis
Martin E. Kreis
RRReinhard Ruppert
Reinhard Ruppert
RKRainer Kube
Rainer Kube
JSJoachim Strassburg
Joachim Strassburg
Susanne MerkelSusanne Merkel
Susanne Merkel

1 October 2010 in Acta Radiologica
Verified
Journal Article
Closed access
PDF file
AHAlexander Huppertz
Alexander Huppertz
TFTobias Franiel
Tobias Franiel
MWMoritz Wagner
Moritz Wagner
OPOlaf Püttcher
Olaf Püttcher
JWJoachim Wagner
Joachim Wagner
JSJoachim Strassburg
Joachim Strassburg
Background: In TNM staging of rectal cancer by MRI, unspecific extracellular contrast agent Gd-DTPA is established for extrahepatic and vascular enhancement whereas liver-specific gadoxetic acid has proven high accurate detection of liver metastasis.